3 Undervalued Dividend Stocks For 2026, According To Yieldly
A deep dive into the 3 undervalued dividend gems flagged by the Yieldly AI Screener (ft. a 7% yielder).
Most investors think you have to choose: you either get High Income or you get Market-Beating Growth.
But seasoned investors know that isn’t true. The most powerful way to compound wealth isn’t chasing stocks hitting all-time highs—it’s buying quality businesses when they are temporarily on sale. While everyone’s talking about the latest hype stocks like Palantir PLTR 0.00%↑, Meta Platforms META 0.00%↑, or Nvidia NVDA 0.00%↑, there are plenty of sleepers out there that remain under valued.
When you buy a dividend stock that is undervalued, you unlock a “Double Engine” for wealth creation:
Higher Income: You lock in a higher starting yield on your capital.
Capital Appreciation: As the valuation reverts to the mean (returns to normal), the stock price rises, giving you aggressive growth on top of your cash flow.
This is how you outperform the market while sleeping well at night.
Using Yieldly’s AI Stock Screener, I searched for this exact setup: Blue-chip companies with reliable dividends that are trading significantly below their intrinsic value. The AI flagged three clear opportunities that are priced for a major rebound.
Here are the 3 undervalued gems I am watching closely.
1. Pfizer PFE 0.00%↑ - The 7% Yield Opportunity
Sector: Healthcare
Dividend Yield: 7.06%
P/E Ratio: 15.0x
Yieldly Score: 90/100
Potential Upside: 40.7%
The Bull Case: The market hates uncertainty, and it has punished Pfizer in the post-COVID era. However, this fear has created a massive opportunity for income investors. According to the Yieldly screener, Pfizer is trading at a P/E of 15x, which is lower than the industry average of ~26x. More importantly, the sell-off has pushed the dividend yield to a staggering 7.06%.
PFE recent acquired Metsera, which positions it for growth in the obesity market! Possible Ozempic competitor?
Recent FDA approval of the PADCEV/Keytruda.
PFE’s stock price is now down over 51% from its peak during Covid.
This is a cash-flow monster with strong legacy drugs and a diverse product portfolio. Buying here allows you to lock in a 7% “paycheck” while waiting for the market to realize the company is undervalued. Despite the shortcomings in recent years, mostly driven by sentiment, the stock is extremely undervalued.
2. Merck & Co. MRK 0.00%↑ - The “Strong Buy” Value Play
Sector: Healthcare
Yieldly Score: 95/100
P/E Ratio: 11.2 (vs. Sector Avg 26x)
Dividend Yield: 4.18%
Yieldly’s quick investment report tells us that MRK is a low risk/low volatility stock.
The Bull Case: Merck received one of the highest scores in the entire Yieldly database (95/100), and the valuation tells you why. It is currently trading at a P/E ratio of just 11.2, significantly below the pharmaceutical sector average of 26x. When a company with a robust pipeline of cancer immunotherapies and a history of successful drug launches trades this cheaply, it screams “mispricing.”
This is the definition of a “Double Engine” play: You get a solid reliable dividend, plus the potential for share price expansion as the P/E moves back toward the industry average. MRK has raised its dividend every year, for 14 years straight without interruption.
3. Exxon Mobil XOM 0.00%↑ - The Energy Fortress
Sector: Energy
Dividend Yield: 3.61%
P/E Ratio: 13.0
Yieldly Score: 93/100
The Bull Case: While tech valuations stretch into the stratosphere, the energy sector remains grounded in reality. Exxon Mobil is trading at a P/E of just 13.0, well below the broader market average. With a 3.61% dividend yield and “significant upside potential” flagged by the AI, Exxon offers a perfect hedge against inflation and volatility. It has a diversified energy portfolio and a global presence that makes it a cornerstone for any serious income portfolio.
How I Find These “Fat Pitches”
Wall Street has teams of analysts looking for these discrepancies. I use Yieldly.
The AI Stock Screener instantly filters the noise to find companies with high Yieldly Scores—meaning they have the perfect balance of Safety, Value, and Income. Instead of guessing which stocks are cheap, I let the data tell me where the value is hiding.
Stop overpaying for income. Start finding value.
👉 Try the Yieldly AI Screener Today (5% Off for Subscribers that made it to the end of this article)